Interventional Oncology Market Overview
The global interventional oncology market is projected to expand at a CAGR of approximately 11% during the forecast period. Market growth is being supported by the rising global burden of cancer, increasing preference for minimally invasive treatment approaches, improvements in medical imaging, an aging population, and greater awareness of image-guided cancer interventions among healthcare professionals.
Interventional oncology combines oncology, radiology, and minimally invasive techniques to diagnose, treat, and provide palliative care for cancer patients. Procedures are generally performed using imaging technologies to precisely target tumors while minimizing damage to surrounding healthy tissues.
The increasing incidence of liver, lung, colorectal, kidney, breast, and other cancers is creating a growing patient pool for interventional oncology procedures. At the same time, healthcare providers are increasingly adopting image-guided interventions as complementary or alternative treatment approaches for selected cancer patients.
For instance, in June 2023, data published by the U.S. Centers for Disease Control and Prevention (CDC) indicated that the U.S. recorded 1,603,844 new cancer cases and 602,347 cancer-related deaths in 2020. The substantial cancer burden highlights the continuing need for innovative treatment approaches, including minimally invasive interventional oncology procedures.
Increasing investments by medical device companies and research organizations in novel ablation systems, embolization technologies, imaging platforms, and targeted therapies are also supporting market development.
The COVID-19 pandemic temporarily disrupted the interventional oncology market. Lockdowns, reduced hospital capacity, and the postponement of non-emergency procedures resulted in fewer cancer-related hospital visits and delays in diagnosis and treatment. However, the gradual lifting of restrictions resulted in a recovery in oncology-related hospital activity as patients returned for postponed procedures and treatments.
Interventional Oncology Market Trends
Growing Adoption of Radioembolization
Radioembolization is emerging as an important treatment approach within interventional oncology. The minimally invasive technique involves delivering radioactive microspheres through blood vessels supplying a tumor, allowing radiation to be concentrated within the targeted area.
The technique has traditionally been associated with liver cancer treatment, but its potential applications are expanding. Researchers and healthcare providers are investigating radioembolization for additional malignancies, including metastatic colorectal cancer and neuroendocrine tumors.
For instance, in June 2022, research published by the Radiological Society of North America reported a median survival of approximately 15 months following transarterial radioembolization (TARE) using yttrium-90 microspheres in patients with metastatic colorectal cancer.
The expansion of radioembolization into additional cancer indications is expected to increase demand for associated devices and procedural technologies. Manufacturers are also working to improve microsphere design, delivery systems, imaging guidance, and treatment planning to increase procedural precision and safety.
Advances in imaging technologies are particularly important because accurate tumor visualization and treatment planning can improve the targeting of cancerous tissue while reducing exposure to healthy tissue.
Increasing Integration of Advanced Imaging
Imaging plays a central role in interventional oncology because it enables physicians to visualize tumors, guide instruments, plan procedures, and monitor treatment outcomes.
Advances in computed tomography, magnetic resonance imaging, ultrasound, cone-beam CT, and other imaging technologies are improving procedural accuracy.
The integration of advanced imaging with artificial intelligence and treatment-planning software is also creating opportunities to improve tumor detection, treatment planning, and procedural navigation.
As image-guided systems become more sophisticated, healthcare providers are increasingly able to perform complex procedures with greater precision and potentially lower procedural risks.
Market Drivers
Growing Global Prevalence of Cancer
The rising prevalence of cancer is one of the primary factors supporting the growth of the interventional oncology market. Increasing incidence of liver, lung, colorectal, breast, kidney, and other cancers is expanding the number of patients requiring diagnosis, treatment, and palliative care.
According to data from the World Health Organization (WHO) cited in February 2024, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were estimated globally in 2020.
The growing cancer burden is increasing pressure on healthcare systems to provide effective and less invasive treatment options. Interventional oncology procedures can provide localized treatment for selected tumors and may be used alongside surgery, systemic therapy, or radiation therapy.
The increasing focus of pharmaceutical and medical technology companies on developing novel oncology therapies is also creating opportunities for interventional approaches that can complement drug-based treatments.
Preference for Minimally Invasive Procedures
The shift toward minimally invasive cancer treatment is another major market driver. Patients and healthcare providers increasingly prefer procedures that can achieve therapeutic objectives while minimizing tissue damage and recovery time.
Compared with conventional open surgery, minimally invasive interventions can offer advantages such as smaller incisions, reduced postoperative pain, shorter hospital stays, faster recovery, and potentially fewer complications for appropriately selected patients.
Interventional oncology procedures such as radiofrequency ablation, microwave ablation, cryoablation, and image-guided embolization are designed to target tumors with limited disruption to surrounding tissues.
A comparative study published through NCBI in January 2021 examining minimally invasive surgery and open surgery in China reported lower complication rates among patients undergoing minimally invasive procedures.
Growing awareness of these benefits among patients and healthcare professionals is expected to encourage broader adoption of minimally invasive oncology procedures.
Key Request a free sample copy or view report summary: https://meditechinsights.com/global-interventional-oncology-market/request-sample/
Market Restraints
High Procedural Costs and Limited Specialized Expertise
The high cost of interventional oncology procedures remains a significant barrier to market expansion. Advanced equipment, imaging systems, ablation technologies, embolization devices, and specialized treatment infrastructure require considerable investment.
Healthcare facilities may also need to upgrade operating environments and imaging capabilities to accommodate advanced image-guided procedures. These requirements can be particularly challenging for smaller hospitals and healthcare facilities operating with limited capital budgets.
The shortage of trained interventional oncologists and other specialized healthcare professionals represents another important constraint.
Interventional oncology procedures require specialized knowledge of oncology, interventional radiology, imaging, and procedural techniques. Physicians and supporting clinical teams often require extensive training before they can independently perform complex interventions.
The shortage of qualified professionals is particularly challenging in emerging and developing markets, where access to specialized training programs and advanced cancer treatment infrastructure may be limited.
As a result, patients in underserved regions may experience delays in accessing minimally invasive oncology treatments, limiting the penetration of advanced interventional technologies.
Regulatory and Reimbursement Challenges
Innovative interventional oncology technologies often require extensive clinical evaluation and regulatory approval before they can be widely commercialized.
Manufacturers must demonstrate the safety, effectiveness, and reliability of new devices and treatment systems, which can increase development costs and extend commercialization timelines.
Reimbursement policies can also influence adoption. Hospitals and physicians may be reluctant to invest in advanced technologies when reimbursement levels do not adequately cover the cost of equipment, personnel, and procedures.
Greater regulatory clarity, clinical evidence, and favorable reimbursement frameworks could therefore support wider adoption of emerging interventional oncology technologies.
Market Opportunities
Expansion of Image-Guided and Ablation Technologies
The increasing development of image-guided ablation technologies represents a significant opportunity for market participants. Radiofrequency ablation, microwave ablation, cryoablation, and other localized treatment technologies are being refined to improve tumor targeting and treatment outcomes.
Advances in imaging, navigation, robotics, artificial intelligence, and treatment-planning software could further improve procedural precision.
The combination of imaging and therapeutic technologies is also supporting the development of integrated treatment platforms capable of guiding physicians throughout the intervention.
Growing Use in Emerging Markets
Emerging economies represent an important opportunity because cancer incidence is increasing while access to advanced oncology care remains uneven.
Healthcare infrastructure investments, cancer awareness programs, improvements in diagnostic capabilities, and increasing healthcare expenditure can support the adoption of interventional oncology technologies in these markets.
Manufacturers that develop cost-effective, scalable, and easy-to-use technologies may be well positioned to expand access to image-guided cancer treatment in underserved regions.
Competitive Landscape Analysis
The global interventional oncology market includes major medical device manufacturers, imaging companies, interventional technology providers, and specialized oncology solution developers. Companies are competing through new product launches, technology upgrades, strategic partnerships, clinical research, acquisitions, and geographic expansion.
Market participants are increasingly focusing on improving the precision, safety, and efficiency of minimally invasive oncology procedures. Investments in ablation technologies, embolization systems, imaging platforms, treatment-planning software, and integrated image-guided solutions are expected to remain important competitive strategies.
The integration of artificial intelligence, advanced imaging, robotics, and data analytics is also expected to create opportunities for companies to differentiate their products and improve procedural workflows.
Key Players
- Medtronic plc
- Boston Scientific Corporation
- Johnson & Johnson
- Cook Medical
- Becton, Dickinson and Company
- AngioDynamics, Inc.
- Stryker Corporation
- B. Braun Melsungen AG
- Terumo Corporation
- Siemens Healthineers
- GE HealthCare
The competitive landscape is expected to remain dynamic as established companies and emerging technology developers continue to introduce innovative solutions for minimally invasive cancer treatment. Strategic collaborations between medical device companies, hospitals, research institutions, and oncology centers are likely to support the development and clinical adoption of new technologies.
Key Request a free sample copy or view report summary: https://meditechinsights.com/global-interventional-oncology-market/request-sample/
Overall, the interventional oncology market is positioned for strong growth as cancer incidence continues to rise and healthcare systems increasingly prioritize minimally invasive, targeted, and image-guided treatment approaches. Continued advances in radioembolization, ablation, imaging, artificial intelligence, and treatment planning are expected to expand the role of interventional oncology in cancer care through the forecast period.
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
